These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 25286972)

  • 21. Inducing synthetic lethality using PARP inhibitors.
    Boss DS; Beijnen JH; Schellens JH
    Curr Clin Pharmacol; 2010 Aug; 5(3):192-5. PubMed ID: 20406170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olaparib for the treatment of breast cancer.
    Griguolo G; Dieci MV; Guarneri V; Conte P
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):519-530. PubMed ID: 29582690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP inhibitors: its role in treatment of cancer.
    Chen A
    Chin J Cancer; 2011 Jul; 30(7):463-71. PubMed ID: 21718592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
    Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J
    Lancet; 2010 Jul; 376(9737):235-44. PubMed ID: 20609467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
    Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
    Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [PARP inhibitors and breast cancer: update and perspectives].
    Gonçalves A
    Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
    Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
    Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
    Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
    J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olaparib Keeps Hereditary Breast Tumors in Check.
    Cancer Discov; 2017 Aug; 7(8):OF10. PubMed ID: 28583909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
    Mendes-Pereira AM; Martin SA; Brough R; McCarthy A; Taylor JR; Kim JS; Waldman T; Lord CJ; Ashworth A
    EMBO Mol Med; 2009 Sep; 1(6-7):315-22. PubMed ID: 20049735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
    Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
    Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP-inhibitors in BRCA-associated pancreatic cancer.
    Bhalla A; Saif MW
    JOP; 2014 Jul; 15(4):340-3. PubMed ID: 25076338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
    J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
    Helleday T
    Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
    Pessetto ZY; Yan Y; Bessho T; Natarajan A
    Breast Cancer Res Treat; 2012 Jul; 134(2):511-7. PubMed ID: 22562176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.